Stockreport

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications [Yahoo!...

Halozyme Therapeutics, Inc.  (HALO) 
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: halozyme.com/investors/default.aspx
PDF SAN DIEGO March 31, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received a positive opinion fro [Read more]